Stockscreener 앱 받기
30.79
4.91%
1.44
시간 외 거래:
30.73
-0.06
-0.19%
전일 마감가:
$29.35
열려 있는:
$29.7
하루 거래량:
250.86K
Relative Volume:
1.63
시가총액:
$486.54M
수익:
$925.00K
순이익/손실:
$-98.64M
주가수익비율:
-6.1346
EPS:
-5.0191
순현금흐름:
$-83.37M
1주 성능:
+9.93%
1개월 성능:
+3.25%
6개월 성능:
+60.87%
1년 성능:
+67.16%
1일 변동 폭
$29.00
$32.23
1주일 범위
$27.75
$32.23
52주 변동 폭
$14.65
$37.27
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
30.79 | 471.84M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Craig Hallum | Buy |
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Inc. (NGNE) Holds Steady Near Resistance as Biotech Sector WatchesBreakaway Gap - newsline.com
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues R&D InvestmentEPS Surprise History - newsline.com
NGNE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $70 - GuruFocus
Neurogene stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
NGNE Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress ContinuesGAAP Earnings Report - newsline.com
Neurogene (NGNE) Completes Dosing in Key Trial for NGN-401 - GuruFocus
Number of shareholders of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene Completes Dosing in Pivotal Embolden™ Trial of NGN-401 Gene Therapy for Rett Syndrome - Minichart
Neurogene Completes Dosing in Embolden Rett Trial - TipRanks
Neurogene completes dosing in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria
Neurogene completes dosing in Embolden trial, doses 25 participants; topline data due 2H 2027 - TradingView
Neurogene Inc. finalizes administration phase in pivotal Embolden study - Traders Union
Neurogene completes dosing in Rett syndrome gene therapy trial - Investing.com
Neurogene (NGNE) finishes dosing in NGN-401 Embolden Rett registrational trial - Stock Titan
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome - The Joplin Globe
25 girls receive Neurogene’s one-time gene therapy in key Rett syndrome trial - Stock Titan
Neurogene Inc. Files Form 8-K with SEC Detailing Corporate Information and NASDAQ Listing - Minichart
Neurogene Stockholders Vote on Directors and Executive Pay - TipRanks
Neurogene (NGNE) investors back board slate, pay plan and auditor - Stock Titan
NGNE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rodman & Renshaw initiates Neurogene stock with buy on gene therapy - Investing.com Nigeria
Two new Neurogene hires get options on 17,045 company shares - Stock Titan
Neurogene Inc. (NGNE) Gains 3% as Biotech Sentiment Lifts SharesETF Outflow Streak - newsline.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
Neurogene’s Stock Run Is Riding A Rett Gene Therapy Bet - Finimize
NGNE Stock Chart | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
Neurogene Inc. (NGNE) Shows Resilience: Gains 2.45% as Biotech Sector Looks to ReboundCrowd Entry Signals - newser.com
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear - Bez Kabli
Neurogene (NGNE) Q1 2026 Results Miss Estimates — EPS $-1.39 vs $-1.32Slow Growth Warning - Newser
NGNE News | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Neurogene (NGNE) Stock: Down -4.22%, Support Test at $28.45 2026-05-15Turnaround Stocks - Newser
Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18 - MSN
Neurogene Inc. Stock 12‑Month Price Target Raised to $77.86, Implies 147% Upside - TradingView
Neurogene 1Q Loss $30.9M >NGNE - Moomoo
Neurogene : Corporate Presentation May 2026 - marketscreener.com
Neurogene: Q1 Earnings Snapshot - marketscreener.com
Neurogene Q1 net loss widens on higher R&D costs - TradingView
Rett gene therapy trial nears full dosing, no HLH cases at 1E15 vg - Stock Titan
Rett gene therapy progress highlights Neurogene (NGNE) Q1 2026 update - Stock Titan
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Neurogene (NGNE) boosts Rett R&D as Q1 2026 net loss deepens - Stock Titan
Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026 - Traders Union
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - The Norfolk Daily News
Neurogene Inc (NGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):